Swiss National Bank Has $22.17 Million Stake in Insmed Incorporated (NASDAQ:INSM)

Swiss National Bank raised its position in Insmed Incorporated (NASDAQ:INSM) by 6.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 321,100 shares of the biopharmaceutical company’s stock after purchasing an additional 18,600 shares during the quarter. Swiss National Bank owned 0.18% of Insmed worth $22,169,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Insmed by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock valued at $278,432,000 after buying an additional 172,664 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after acquiring an additional 214,130 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after purchasing an additional 850,000 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Insmed by 7.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,546,607 shares of the biopharmaceutical company’s stock worth $106,778,000 after purchasing an additional 102,341 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in Insmed by 2.6% in the third quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company’s stock valued at $70,260,000 after purchasing an additional 24,025 shares during the period.

Analyst Ratings Changes

INSM has been the topic of a number of analyst reports. UBS Group upped their price target on Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Truist Financial increased their target price on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Finally, Stifel Nicolaus dropped their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Insider Activity

In related news, insider Martina M.D. Flammer sold 6,172 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the transaction, the insider now owns 101,549 shares in the company, valued at approximately $6,462,578.36. This represents a 5.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $27,079,091.58. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 550,957 shares of company stock valued at $42,859,028 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $77.77 on Tuesday. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The stock’s 50 day moving average is $76.39 and its 200-day moving average is $73.70. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $14.08 billion, a price-to-earnings ratio of -13.91 and a beta of 1.28.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Sell-side analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.